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Abstract 
Purpose: To synthesize a series of novel thiazolo pyrimidine derivatives and evaluate them in vitro and 
in vivo for their safety and anti-leishmanial activity using BALB/c mice. 
Methods: Substituted pyrazolopyrimidine and pyrazolopyrazole were synthesized by reacting amino 
group of 2-amino-4-cyano-pyrazol]naphthalino[1,2-d]thiazole with a variety of formamide or hydrazine 
hydrate. The synthesized compounds were characterized by nuclear magnetic resonance spectroscopy 
(1H-NMR) and mass spectroscopy (MS). The purity of the compounds was determined by elemental 
analysis. Safety and anti-leishmanial activity of the compounds were determined in vitro by i) viability 
assessment of leishmania-infected macrophages, relative abundance of IL-12p40 mRNA gene 
expression and levels of IL10 /IL-12 determination in supernatants of cultured macrophages treated with 
2.5 and 10 µM of the compounds, using microscope cell counting, reverse transcriptase polymerase 
chain reaction (RT-PCR) and enzyme linked immunosorbent assay (ELISA), respectively. ii) cytotoxicity 
of the compounds evaluated by determination the safety index as IC50 of the compound in 
macrophages/IC50 of the compound in amastigotes. iii) bioassay at 16 weeks post-infection of mice 
treated with the reference drug, the tested compound alone and both the compound with IL-12. Disease 
progression and footpad thickness were evaluated regularly during treatment. 
Results: Compound 4 emerged as the most active anti-protozoal compound of the series against 
Leishmania viability (activity 60 %) compared with the reference drug (activity 65 %). When it was 
combined with IL-12, the activity reached 90 %.  
Conclusion: Compound 4 can serve as a lead molecule for further development to a clinically useful 
novel class of agents. 
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Leishmaniasis, caused by the protozoan parasite 
of the genus Leishmania, affects over 12 million 
individuals worldwide, 1.5 – 2 million of whom 
develop symptomatic disease every year [1]. The 
parasite is spread by the sand fly vector and 
causes a spectrum of diseases depending on the 
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parasite species and the host immune status. 
Clinical manifestations of the disease range from 
self-limiting cutaneous Leishmaniasis, disfiguring 
muco-cutaneous Leishmaniasis, to fatal visceral 
leishmaiasis. Current treatment use toxic 
antimonial compounds. These treatments are 
laborious and expensive, cause severe side 
effects and emerging drug resistance has been 
reported [2]. Therefore, an alternative effective 
treatment regime would be desirable.   
 
Immunity against L. major infection is well 
characterized in the mouse model and depends 
mainly on T-helper1 (Th1) immune responses 
mediated by CD4+ T cells induced by the 
essential cytokine IL-12 [3]. As Leishmania 
reside within macrophages, they deviously 
manipulate the host innate and acquired immune 
mechanisms. This ensures their survival within 
the hostile environment of macrophages and 
hinges on their capacity to modulate macrophage 
effect or functions including production of 
reactive nitrogen intermediates, RNI [4]. 
Macrophages can induce host cells to produce 
cytokines that promote disease progression via 
regulation of Th1 and Th2 cells. The Th1 cells by 
secreting IFN-δ enhance macrophage microbial 
activity, thus protecting the host from intracellular 
Leishmania pathogens [5]. Conversely, the 
parasite for survival cleverly augments Th2 
response, leading to an increased secretion of 
IL-4 and IL-10, resulting in attenuation of the host 
mechanisms and Leishmania infection ensues 
[6]. 
 
Newly synthesized pyrimidine and  pyrazolo 
derivatives are well documented [7,8]. Hetero 
cyclic compounds exhibit anthelmintic, anti HIV 
activity and hypoglycemic activity [9], anti-
microbial, analgesic [10,11], against herpes 
simplex virus type-1 (HSV-1) and hepatitis-A 
virus (HAV), serotonin 5-HT6 receptor antagonist 
[12], antitumor activity and anticancer activity 
[13]. Thiazolopyrimidines have hypoglycemic, 
hypolipidemic, anti-diabetic, [14] and antimalarial 
[15,16]. As an extension of our ongoing studies, 
the objective of the present work is to synthesize 
new compounds and evaluates them both in vitro 
and in vivo for their anti-protozoal activities 





In a previous work, we have reported the 
synthesis of substituted pyrazolopyrimidine 3 and 
pyrazolopyrazole 4 by using 1-(naphtho[1,2-
d]thiazol-2-yl)hydrazine 1 as starting material. 
The starting material 1 was synthesized 
according to the previous procedure [17] 
(Scheme 1). 
 
The reaction of compound 1 with 
ethoxymethylene malomonitrile afforded the 
corresponding 3-amino-4-cyanopyrazolo 
derivatives 2, which was treated with formamide 
or hydrazine hydrate to produce the 
corresponding 3-aminopyrazolopyrimidine 3 and 
aminopyrazolopyrazole derivative 4, respectively 


















Scheme 1: Synthetic route of 1-(naphtho[1,2-d]thiazol-2-yl)hydrazine 1 
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Scheme 2: Synthetic route of compounds 2-4 
 
Synthesis of 2-[3-amino-4-cyano-pyrazol-2-yl] 
naphthalino [1,2-d]thiazole (2)  
 
A mixture of compound 1 (0.01 mol) and 
ethoxymethylene malononitrile (0.01 mol) in 
absolute ethanol (30 mL) was refluxed for 2h. 
The solvent was evaporated under reduced 
pressure; the residual solid was crystallized from 
ethanol to give the title product 2 as yellow 
powder. Yield 87 %; m.p. 256-258 °C; IR (KBr, 
cm-1): 3345-3315 (NH2) and 2215 (CN) cm-1; 1H-
NMR (DMSO-d6): δ = 6.78-7.61 (m, 7H, 6Ar-H 
and 1HPyrazolo) and 10.43 (b, 2H, NH2 
exchangeable with D2O) ppm; MS m/z (%) = 291 
(M+, 23) corresponding to the molecular formula 





A solution of compound 2 (0.01 mol) in 
formamide (20 ml) was refluxed for 2h. After 
cooling, the solid product was collected by 
filtration, dried and crystallized from methanol to 
give the title product 3 as reddish brown powder 
Yield 66 %; m.p. 290-292 °C; IR (KBr, cm-1): 
3325 (NH2) cm-1; 1H-NMR (DMSO-d6): δ= 6.64-
7.52 (m, 8H, 6Ar-H, 1HPyrazolo and 1HPyrimidino) and 
11.12 (b, 2H, NH2 exchangeable with D2O) ppm; 
MS m/z (%) = 318 (M+, 19) corresponding to the 




c]pyrazol-2-yl]naphthalino[1,2-d]thiazole (4)  
 
A mixture of compound 2 (0.01 mol), and 
hydrazine hydrate (0.01 mol) in acetic acid (30 
mL) was refluxed for 3 h. The reaction mixture 
was poured onto ice cold water. The solid was 
filtered off, dried and crystallized from ethanol to 
give title product 4 as green powder. Yield 69 %; 
mp > 300 °C; IR (KBr, cm-1): 3372-3323 (NH, 
NH2) cm-1; 1H-NMR (DMSO-d6): δ= 6.15 (s, 1H, 
NH exchangeable with D2O), 7.21-7.58 (m, 7H, 
6Ar-H and 1HPyrazolo) and 11.42 (b, 2H, NH2 
exchangeable with D2O) ppm; MS m/z (%) = 306 
(M+, 31) corresponding to the molecular formula 




Five to 6- week- old BALB/c mice of either sex, 
16-18 g each were purchased from Theodor 
Bilharz Research Institute TBRI, Egypt. Approval 
of the institutional Animal Ethical Committee for 
the animal studies was obtained from the Office 
of Environmental Health and Radiation Safety 
(ACUC protocol # 1096-5). The animals were 
maintained according to accepted standards of 




Promastigotes from Indian Leishmania donovani 
isolate (NS2) were routinely passaged in mice 
and after transformation, cultured at 24 oC in 
medium 199 supplemented with 10 % heat 
inactivated fetal calf serum (HIFCS), Penicillin G 
(50 IU/mL) and Streptomycin (50 µg/mL). For 
infection of macrophages, 24 h prior to the 
experiment, stationary phase promastigotes were 
centrifuged and the pellet re-suspended in 
Schneider's insect medium supplemented with 
20 % HIFCS, pH 5.5, as described by [20] 
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In vitro anti-amastigote activity in 
macrophages 
 
Peritoneal macrophages lavaged from BALB/c 
mice were seeded in 16 chamber slides (1.5 x 
105/200 µl/well of complete RPMI-1640 medium) 
and after a 2 - 4 h incubation at 37 oC, 5 % CO2, 
the supernatants (containing lymphocytes) were 
gently removed and kept aside at 37 oC, 5 % 
CO2. Adherent macrophages were then infected 
with stationary phase L. donovani promastigotes 
(preconditioned at 25 oC for 24 h in Schneider's 
insect medium pH 5.5 at a macrophage: parasite 
ratio of 1: 10 and incubated for 5 h at 37 oC, 5 % 
CO2. After removal of non-internalized parasite, 
macrophages were then co-cultured with the 
above mentioned supernatants in the presence 
or absence of compound 3 and compound 4 
separately at a dose of  (0 - 25 µM) for 72 h, after 
which cells were fixed., Giemsa-stained (diluted 
1:7 in deionized water, pH 6.8) and examined 
microscopically for intracellular amastigotes. At 
least 100 macrophages/well were counted to 
calculate the percentage of infected 
macrophages. The infection rate of treated 
macrophages was normalized to 100 % for 
further analysis. 
 
Safety index of the synthetic compounds 
 
To investigate the cytotoxicity of the compounds, 
murine macrophages (1.5 x 105/200 µl/well) were 
incubated with the compounds (0 - 100 µM) at 37 
oC, 5 % CO2 for 48, 72 and 96 h and cell viability 
enumerated as described by [21]. The safety 
index was calculated as the IC50 of the 
compound in macrophages/ IC50 of compound in 
amastigotes. 
 
Reverse transcriptase polymerase Chain 
reaction (RT-PCR) 
 
Total RNA was isolated using the RNAqueous Kit 
from normal and Leishmania-infected 
macrophages (obtained from BALB/c mice) after 
being treated the tested compound (2.5 and 10 
µM) for 18 h. Subsequently, RT-PCR was carried 
out with the one-step RT-PCR kit using (200 
ng/reaction) that was reverse-transcribed into 
cDNA and amplified, using gene-specific primers 
as described previously [22]. 
 
IL-10 and IL-12 measurement using sandwich 
ELISA  
 
Levels of mouse IL-10 and IL-12p40 present in 
the supernatants of uninfected and L. donovani 
infected macrophages that had been treated with 
the compounds for 24 h were measured using an 
ELISA kit as per the manufacturer's instruction. A 
standard curve with a cytokine-positive control 
was run in each assay, the lower limit of 
detection being 31.24 pg/mL for IL-10 and 15.0 
pg/mL for IL-12p40.  
 
Parasite Infection and tissue studies 
 
Mice were inoculated in one hind footpad with 
metacyclic promastigotes. A total of 1-2 x 105 
highly infective stage metacyclic promastigotes 
was isolated from stationary culture (5-7 d old) by 
negative selection using peanut agglutinin 
(Vector laboratories, Burlingame, CA) and 
injected subcutaneously in the left footpad. The 
infected footpad was kept under observation 16 
weeks after infection for redness, swelling, 
ulceration, crust formation or gangrenous 
changes. The evolution of the lesion was 
monitored weekly by measuring footpad 
thickness using metric caliper (Mitutoyo 
Measuring Instruments, Aurora, IL). The degree 
of infection in parasitized footpad lesions was 
determined by limiting dilution analysis of 
homogenized tissue. To determine parasite 
concentrations, footpads were weighed and 
homogenized. Two-fold serial dilutions of the 
homogenized tissue suspensions were then 
plated in 96-well plates and incubated at 26 oC 
for 7-10 days. Wells were examined for viable 
and motile promastigotes, and the highest 
dilution that was positive for parasites was 
considered to be the parasite concentration per 
milligram of tissue. The total parasite burden was 
calculated using the weight of the footpad, as 
previously described [23]. 
 
Animal's treatment regime 
 
Sodium stibogluconate (Pentostam, Burroughs 
Welcome, London, United Kingdom) containing 
100 mg of pentovalent antimony per ml) was a 
gift of Max Grog, Walter Reed Army Institute of 
Research, Washington, D.C. Mouse recombinant 
IL-12, kindly provided by Giorgio Trinchieri 
(Wistar Institute, Philadelphia, PA). Animals were 
divided into experimental groups (GPs), 45 mice 
each, GP1: untreated infected control, received 
intradermal injection of 2 x 107 viable 
promastigotes in the right footpad; GP2: Infected 
and treated with the reference drug (Sodium 
stibogluconate), each mice received a total of 10 
daily intramuscular injections with 250 mg of drug 
per kg of body weight during weeks 3 and 4 of 
infection; GP3: infected and treated with 
compound 4, each mice received a total of 10 
daily intramuscular injections with 25 mg of the 
compound per kg of body weight during weeks 3 
and 4 of infection; GP4: infected and treated with 
compound 4 as mentioned before + IL-12 (0.1 
mL containing 0.1 µg of IL-12 ) intraperitoneally 
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on day 15 of infection with an additional dose on 
day 22 of infection. One group was used as 
normal non-infected control, injected with 0.1 mL 




The results are expressed as mean± SD/SEM as 
indicated. Statistical analysis was based on one-
way ANOVA followed by Turkey's Multiple 
Comparison Test using Graph Pad Prism 





Anti-leishmanial activity of the synthesized 
compounds 
 
The anti-leishmanial activity of the synthetic 
compounds (0 - 25 µM) was evaluated in terms 
of the intracellular parasite load, wherein the 
infection rate of Leishmania infected 
macrophages was normalized to 100 %; with the 
addition of the tested compound, a dose 
dependent reduction in parasitic load was 
evident, the IC50 being 2.5 µM (Fig. 1). In 
macrophages, 92 % were parasitized and the 
average number of amastigotes/macrophage 
was 11.3. After treatment with the tested 
compound (72 h), the percentage of infected 
macrophages decreased in a dose-dependent 
manner. With 10 µM of the compound, only 59 % 
of macrophages were infected, the number of 




Figure 1: Anti-amastigote activity and safety index of 
the tested compound. Each point corresponds to the 
mean ± SD of at least three experiments in duplicate 
 
The synthetic compounds enhanced mRNA 
expression of IL-12p40 
 
In uninfected macrophages, the tested 
compound (2.5 and 10 µM) induced an increase 
in mRNA expression of IL-12p40. Following 
infection with Leishmania parasites (as confirmed 
by Giemsa staining), a down regulation in mRNA 
expression of IL-12p40 was observed, which was 




Figure 2: Effect of the tested compound on mRNA 
gene expression of IL-12p40 in macrophages 
 
This genetic up-regulation of IL-12p40 by the 
tested compound was correlated by quantifying 
levels in culture supernatants by ELISA. In 
uninfected macrophages, the mean ± SEM was 
495.00 ± 26.53 pg/mL, which with the tested 
compound (2.5 and 10 µM) significantly 
increased by 1.85 and 1.9 fold (p < 0.001) 
respectively. Following successful intracellular 
Leishmania infection, levels of IL-12 reduced 
significantly by 1.7 fold, (p < 0.001), importantly, 
treatment with the synthetic compound (2.5 and 
10 µM) significantly increased production of IL-
12p40 to 550.8 ± 60.5 (p < 0.05) and 595.1 ± 
32.98 pg/mL (p < 0.01) respectively compared 
with infected macrophages (Fig. 3).The tested 
compound (2.5 and 10 µM), significantly 
decreased the secretion of IL-10 as compared 




Figure 3: Effect of the tested compound on IL-12p40 
level in macrophages culture supernatants Each point 
represents the mean ± SEM of IL-12p40 (pg/mL) of at 
least 3 experiments in duplicate 
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Cutaneous lesion and the parasitological 
footpad tissue studies 
 
Early onset was observed in the infected control 
group (GP1), where swelling, ulceration and 
gangrene formation were observed in the 
majority of mice and the lesion developed up to 
total gangrene and auto-amputation. Later onset 
was observed in the reference drug treated 
group (GP2), up to ulceration with minority of 
mice developed gangrene and only 2 mice 
developed auto-amputation. Also, the latest 
onset was observed in the compound 4 treated 
group (GP3) and the combination treated group 
(GP4) up to ulceration with no gangrene or 
amputation, where the ulcers were slow 
developing, healing and only observed in the 
minority of mice as shown in (Table 1). There 
was a dramatic lessening of disease progression, 
as seen by reduction of footpad swelling in mice 
treated with the compound 4 combined with IL-12 





In a previous work, we have reported the 
synthesis of pyrazolopyrimidine and 
pyrazolopyrazole derivatives using 
hydrazinothiazole 1 as starting material. The 
reaction of α-amino naphthol with KSCN 
produced 2 amino thiazolo derivatives. The 
reaction of 2-amino thiazolo derivatives with 
sodium nitrite and hydrochloric acid produced the 
corresponding diazoium salt, which converted to 
2- hydrazine thiazolo derivatives 1 (Scheme 1). 
Reaction of hydrazinothiazolo derivatives 1 with 
ethoxymethylene afforded compound 2, which 
reacted to formamide and hydrazine hydrate 
respectively to produce pyrazolopyrimidine 3 and 
pyrazolopyrazole 4 respectively (Scheme 2). All 
the synthesized compounds were confirmed by 
spectral data (IR, 1H-NMR and mass spectra). 
Structure-activity relationships based on the 
obtained results indicated that substitution of 2-
[6-aminopyrimidino[4,5-c]pyrazol-2-yl]naphthalino 
[1,2-d]thiazole 3 derivatives had anti-leishmanial 
activity and safety effect. 
 
We initially investigated whether the new 
synthetic compounds 3 and 4 affect the 
amastigote activity inside Leishmania infected 
macrophages and affect the IL-12 mRNA gene 
expression with IL-10, IL-12 cytokines secretion 
levels. In uninfected macrophages, the tested 
compounds (2.5 and 10 µM) induced an increase 
of IL-12p40 mRNA gene expression. Following 
infection with Leishmania parasite a down-
regulation of this protein was observed, which 
was reversed by our new synthetic compounds. 
This genetic up-regulation was correlated with 
the increased levels of IL-12 after treatment of 
infected macrophages with the compounds. 
 
Animal studies showed that compound 4 treated 
group (GP3) achieved a maximum delayed onset 
of cutaneous Leishmaniasis disease progression 
with a decrease of footpad thickness and 
parasite density in the infected footpad compared 
with the infected control group (GP1), specifically 
when combined with the immunotherapeutic 
agent IL-12 (GP4). Our results showed the anti-
leishmanial activity of the synthetic compounds 
were in consistence with previous results showed 
that hetero-cyclic compounds were potent 





The results indicate that the synthesized 
heterocyclic organic compounds, a new series of 
substituted pyrazolopyrimidine 3 and 
pyrazolopyrazole 4, are promising agents for the 
development of new antiprotozoal candidates for 
enhanced safety and pharmacological efficacy 
when augmented with immunotherapy IL-12 for 
the treatment of cutaneous leishmaniasis. 
 





Redness Swelling Ulceration Partial gangrene 
(No. of mice) 
Total gangrene 
(No. of mice) 
Auto-amputation 
GP1 7th day 10th day 5 wks (45) 10 wks (35) 12 wks (42) 14 wks (40) 
GP2 10th day 14th day 6 wks (25) 12 wks (15) 14 wks (10) 16 wks (2) 
GP3 17th day 24th day 8 wks (10) None None None 
GP4 20th day 28th day 9 wks (5) None None None 
GP1= infected control; GP2= Infected and treated with the reference drug; GP3= Infected and treated with 
compound 4; GP4= Infected and treated with both compound 4 and IL-12 
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